The Latest Breaking News from AbbVie

This week we have Tesla (TSLA), Microsoft (MSFT), Alphabet (GOOGL), Exxon Mobil (XOM), Visa (V), Abbvie (ABBV) and Chipotle Mexican Grill (CMG) all set to report.

AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Although Abbvie stock has been lagging behind the broader market over the past year, Wall Street analysts are still moderately bullish about its outlook.

This article covers three buy-rated companies that've increased their dividends for 50+ consecutive years.

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

AbbVie is "firing on all cylinders," an analyst said Friday after the firm beat first-quarter estimates. But AbbVie stock fell.

June S&P 500 E-Mini futures (ESM24) are up +0.63%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.86% this morning as upbeat quarterly results from tech titans Alphabet and Microsoft boosted sentiment, while investors geared up for the release of the Fed’s preferred inflation gauge.

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

The CDC warned doctors about "counterfeit or mishandled" Botox injections that have caused clusters of illness in the U.S.